AstraZeneca issues 9,828 shares under employee schemes

The 9,828 shares are fully fungible with AstraZeneca’s existing ordinary shares and were admitted to trading on the London Stock Exchange Main Market.

Rhea-AI Filing Summary

AstraZeneca PLC issued and admitted 9,828 ordinary shares of $0.25 each under its employee share schemes for September 1, 2026, to September 30, 2026. The shares are fully fungible with existing ordinary shares and were admitted to trading on the London Stock Exchange Main Market under the existing block admission dated January 29, 2021.

Filing Explained

AstraZeneca also reports the post-admission company-wide share count alongside the 9,828 employee-scheme shares issued during the period.

Key Figures

Further ordinary shares issued and admitted: 9,828 shares Nominal value: $0.25 per share Existing block admission date: January 29, 2021

3 metrics

Further ordinary shares issued and admitted 9,828 shares Employee share schemes; September 1, 2026, to September 30, 2026

Nominal value $0.25 per share Ordinary shares

Existing block admission date January 29, 2021 Shares admitted under this block admission

Key Terms

block admission, fully fungible, transferable securities

3 terms

block admission regulatory

"under the Company’s existing block admission"

fully fungible technical

"Fully fungible with existing Ordinary Shares"

transferable securities regulatory

"Details of the transferable securities admitted to trading"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AZN shares were admitted under employee share schemes?

AstraZeneca issued and admitted 9,828 ordinary shares under its employee share schemes for September 1, 2026, to September 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 11:41 AM Accepted by SEC EDGAR 10/01/2026 - 11:40 AM Learn about SEC filing dates

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of October 2026 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Admission of Further Securities to Trading

1 October 2026

Notification of Admission of Further Securities to Trading (PRM 1.6.4R)

The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.

1	Details of the issuer
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
2	Details of the transferable securities admitted to trading
a)	Name, type and identification code	Ordinary Shares of $0.25 each ISIN: GB0009895292
b)	Regulated market	London Stock Exchange - Main Market
c)	Number of further securities issued and admitted	9,828
d)	Total number of securities in issue following admission	1,551,053,289
e)	Fungibility	Fully fungible with existing Ordinary Shares
3	Admission details
a)	Date of admission	Issued between 1 September 2026 to 30 September 2026 (admitted under a block admission dated 29 January 2021)
b)	Prospectus information	Prospectus: N/A Supplementary: N/A Company's webpage: https://www.astrazeneca.com
c)	Coverage of notification	Admission of shares under the Company’s employee share schemes from 1 September 2026 up to 30 September 2026, admitted to trading on the Main Market of the London Stock Exchange under the Company’s existing block admission of shares dated 29 January 2021.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 01 October 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary